Clinical Trial Update: Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nebulized liposomal amphotericin B (Ambisome) for prophylaxis of invasive pulmonary aspergillosis in patients with acute myeloid leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Invasive Pulmonary Aspergillosis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Acute Myeloid Leukemia, Allogeneic Haematopoietic Progenitor Cell Transplant | Phase 2 | Status: COMPLETED